Cargando…

Evolution of antibody immunity following Omicron BA.1 breakthrough infection

Mostrar otras versiones (1)

Understanding the evolution of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we tracked SARS-CoV-2 receptor binding domain (RBD)-specific antibody responses up to six months following Omicron BA.1 breakthrough...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaku, Chengzi I., Starr, Tyler N., Zhou, Panpan, Dugan, Haley L., Khalifé, Paul, Song, Ge, Champney, Elizabeth R., Mielcarz, Daniel W., Geoghegan, James C., Burton, Dennis R., Raiees, Andrabi, Bloom, Jesse D., Walker, Laura M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516849/ https://www.ncbi.nlm.nih.gov/pubmed/36172124 http://dx.doi.org/10.1101/2022.09.21.508922

Ejemplares similares

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2023)

Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron
por: Liu, Hejun, et al.
Publicado: (2022)

Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
por: Moulana, Alief, et al.
Publicado: (2023)

Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains
por: Starr, Tyler N., et al.
Publicado: (2022)

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
por: Moulana, Alief, et al.
Publicado: (2022)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

The Effects of an mRNA Covid-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans
por: Frankel, Arthur E., et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

SARS‐CoV‐2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID‐19 due to Omicron BA.1 and BA.2
por: de Michelena, Paula, et al.
Publicado: (2022)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
por: Guo, Li, et al.
Publicado: (2023)

IBCL-054 The Effects of an mRNA COVID-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans
por: Frankel, Arthur, et al.
Publicado: (2022)

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
por: Wei, Jia, et al.
Publicado: (2023)

A broad and potent neutralization epitope in SARS-related coronaviruses
por: Yuan, Meng, et al.
Publicado: (2022)

A broad and potent neutralization epitope in SARS-related coronaviruses
por: Yuan, Meng, et al.
Publicado: (2022)

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022)

Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone
por: da Silva, Eveline Santos, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
por: Quandt, Jasmin, et al.
Publicado: (2022)

Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients
por: Platen, Louise, et al.
Publicado: (2023)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike
por: Dadonaite, Bernadeta, et al.
Publicado: (2022)

Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses
por: Seaman, Michael S., et al.
Publicado: (2022)

Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection
por: Planas, Delphine, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Omicron breakthrough infections in vaccinated or previously infected hamsters
por: Zhou, Jie, et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
por: Nutalai, Rungtiwa, et al.
Publicado: (2022)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vni0vkk0cmpfeg7o5rp2gktkvo